 |
Previous Article | Next Article 
The Journal of Neuroscience, August 15, 2002, 22(16):6876-6884
Complex Gangliosides at the Neuromuscular Junction Are Membrane
Receptors for Autoantibodies and Botulinum Neurotoxin But Redundant for
Normal Synaptic Function
Roland W. M.
Bullens1, 2,
Graham M.
O'Hanlon3,
Eric
Wagner3,
Peter C.
Molenaar2,
Keiko
Furukawa4,
Koichi
Furukawa4,
Jaap J.
Plomp1, 2, and
Hugh J.
Willison3
Departments of 1 Neurology and
2 Physiology, Leiden University Medical Centre, 2300 RC,
Leiden, The Netherlands, 3 University Department of
Neurology, Institute of Neurological Sciences, Southern General
Hospital, Glasgow, G51 4TF, Scotland, and 4 Department of
Biochemistry II, Nagoya University School of Medicine, Showa-ku, Nagoya
466-0065, Japan
One specialization of vertebrate presynaptic neuronal membranes is
their multifold enrichment in complex gangliosides, suggesting that
these sialoglycolipids may play a major functional role in synaptic
transmission. We tested this hypothesis directly by studying neuromuscular synapses of mice lacking complex gangliosides
attributable to deletion of the gene coding for 1,4
GalNAc-transferase (GM2/GD2 synthase), which catalyzes an early step in
ganglioside synthesis. Our studies show that complex gangliosides are
surprisingly redundant for regulated neurotransmitter release under
normal physiological conditions. In contrast, we show that they are
membrane receptors for both the paralytic botulinum neurotoxin type-A
and human neuropathy-associated anti-ganglioside autoantibodies that
arise through molecular mimicry with microbial structures. These data
prove the critical importance of complex gangliosides in mediating
pathophysiological events at the neuromuscular synapse.
Key words:
complex gangliosides; neuromuscular junction; synaptic
transmission; botulinum neurotoxin; anti-ganglioside antibodies; Miller
Fisher syndrome; 1,4 GalNAc-transferase
Copyright © 2002 Society for Neuroscience 0270-6474/02/22166876-09$05.00/0
This article has been cited by other articles:

|
 |

|
 |
 
J. J. Plomp and H. J. Willison
Pathophysiological actions of neuropathy-related anti-ganglioside antibodies at the neuromuscular junction
J. Physiol.,
August 15, 2009;
587(16):
3979 - 3999.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Kaida, T. Ariga, and R. K Yu
Antiganglioside antibodies and their pathophysiological effects on Guillain-Barre syndrome and related disorders--A review
Glycobiology,
July 1, 2009;
19(7):
676 - 692.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Dong, H. Liu, W. H. Tepp, E. A. Johnson, R. Janz, and E. R. Chapman
Glycosylated SV2A and SV2B Mediate the Entry of Botulinum Neurotoxin E into Neurons
Mol. Biol. Cell,
December 1, 2008;
19(12):
5226 - 5237.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. H. H. Lopez, G. Zhang, M. A. Bianchet, R. L. Schnaar, and K. A. Sheikh
Structural requirements of anti-GD1a antibodies determine their target specificity
Brain,
July 1, 2008;
131(7):
1926 - 1939.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. K. Halstead, F. M. P. Zitman, P. D. Humphreys, K. Greenshields, J. J. Verschuuren, B. C. Jacobs, R. P. Rother, J. J. Plomp, and H. J. Willison
Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model
Brain,
May 1, 2008;
131(5):
1197 - 1208.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Rummel, T. Eichner, T. Weil, T. Karnath, A. Gutcaits, S. Mahrhold, K. Sandhoff, R. L. Proia, K. R. Acharya, H. Bigalke, et al.
Identification of the protein receptor binding site of botulinum neurotoxins B and G proves the double-receptor concept
PNAS,
January 2, 2007;
104(1):
359 - 364.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Dong, F. Yeh, W. H. Tepp, C. Dean, E. A. Johnson, R. Janz, and E. R. Chapman
SV2 Is the Protein Receptor for Botulinum Neurotoxin A
Science,
April 28, 2006;
312(5773):
592 - 596.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. R. Pagani, R. C. Reisin, and O. D. Uchitel
Calcium signaling pathways mediating synaptic potentiation triggered by amyotrophic lateral sclerosis IgG in motor nerve terminals.
J. Neurosci.,
March 8, 2006;
26(10):
2661 - 2672.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. A. Goodfellow, T. Bowes, K. Sheikh, M. Odaka, S. K. Halstead, P. D. Humphreys, E. R. Wagner, N. Yuki, K. Furukawa, K. Furukawa, et al.
Overexpression of GD1a Ganglioside Sensitizes Motor Nerve Terminals to Anti-GD1a Antibody-Mediated Injury in a Model of Acute Motor Axonal Neuropathy
J. Neurosci.,
February 16, 2005;
25(7):
1620 - 1628.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. K. Halstead, G. M. O'Hanlon, P. D. Humphreys, D. B. Morrison, B. P. Morgan, A. J. Todd, J. J. Plomp, and H. J. Willison
Anti-disialoside antibodies kill perisynaptic Schwann cells and damage motor nerve terminals via membrane attack complex in a murine model of neuropathy
Brain,
September 1, 2004;
127(9):
2109 - 2123.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Zhang, P. H. H. Lopez, C. Y. Li, N. R. Mehta, J. W. Griffin, R. L. Schnaar, and K. A. Sheikh
Anti-ganglioside antibody-mediated neuronal cytotoxicity and its protection by intravenous immunoglobulin: implications for immune neuropathies
Brain,
May 1, 2004;
127(5):
1085 - 1100.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. C. Jacobs, G. M. O'Hanlon, R. W. M. Bullens, J. Veitch, J. J. Plomp, and H. J. Willison
Immunoglobulins inhibit pathophysiological effects of anti-GQ1b-positive sera at motor nerve terminals through inhibition of antibody binding
Brain,
October 1, 2003;
126(10):
2220 - 2234.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Dong, D. A. Richards, M. C. Goodnough, W. H. Tepp, E. A. Johnson, and E. R. Chapman
Synaptotagmins I and II mediate entry of botulinum neurotoxin B into cells
J. Cell Biol.,
September 29, 2003;
162(7):
1293 - 1303.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|